Clinical Trials
0
0 active
Approvals
162
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
- McKesson disclosed unauthorized access and data exfiltration from third-party applications in an SEC filing on August 28, 2026, after detecting the intrusion on August 25, 2026. - The extortion group ShinyHunters claims it stole roughly 284 million data records from McKesson's Snowflake and Salesforce environments, a figure representing database rows rather than confirmed unique patients. - Hackers say they used vishing calls to hijack Okta single sign-on accounts, then moved laterally into cloud systems over a four-day window between August 21 and August 25. - ShinyHunters demanded a ransom of $55,236,150 with a 72-hour deadline; McKesson reportedly never responded, and the company has declined to confirm how many individuals were affected.
- McKesson Corporation signed a definitive agreement to acquire Precision Medicine Group, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion. - Following completion, Precision Medicine Group will report within McKesson's Oncology & Multispecialty segment, enhancing clinical trial execution and broadening clinical service offerings. - The acquisition strengthens McKesson's oncology and multispecialty strategy by adding biomarker intelligence, lab services, a global CRO, and market access consulting capabilities. - The deal reflects broader industry consolidation, complementing a separate Lundbeck–Eversana partnership focused on AI-powered commercialization.
- Precipio (PRPO) combines clinical laboratory services with proprietary diagnostic product development, with pathology services focused primarily on hematologic cancers. - Biodesix (BDSX) provides blood-based diagnostic testing for lung disease, including tests that assess cancer risk in lung nodules and guide post-diagnosis treatment. - Biodesix has outperformed Precipio over the past three months (up 64.5% vs. 26.4%) and over the past year (up 150.9% vs. 112%). - Both stocks trade below the Zacks Medical sector average EV/S of 2.92X, with PRPO at 1.90X and BDSX at 2.89X.
- Veristat announced four strategic leadership appointments to strengthen its biostatistics, drug development advisory, and human resources capabilities. - Dr. Zhaohui Su and Dr. Gil Fine join the Strategic Drug Development Advisory team, bringing decades of biostatistical expertise from IQVIA, McKesson, Syntex, and Sumitomo Dainippon Pharma Oncology. - Scott Tarrant was named Executive Vice President to lead the Strategic Drug Development consultancy globally, while Clint Wolfe joins as Chief Human Resources Officer. - The hires build on Veristat's 30-year foundation in biostatistics and its recent acquisition of Certara's medical writing and regulatory submission business.
- Health system pharmacists are taking on expanded roles in data analytics, supply chain navigation, payer access, and AI-driven clinical decision-making, according to McKesson's 2026 outlook report. - Pharmacy technicians are being upskilled for advanced tasks including medication history intakes, quality and safety verification, and management of automated EHR and inventory systems. - Specialty pharmacy services increasingly demand expertise in value-based care models, oncology, immunotherapy, gene/cell therapies, and insurance navigation including 340B and CMS reimbursement rules. - Automation and AI integration across all skill levels require new proficiencies in informatics, technology management, and policymaking to govern emerging tools while freeing pharmacists for top-of-license activities.
- Late August 2026 saw a coordinated wave of cyberattacks on healthcare and critical infrastructure, disrupting medical care and compromising patient data. - Boston Scientific suffered a major hack that disrupted customer order processing and halted activation of new remote patient monitoring systems. - McKesson faced a breach by the ShinyHunters group, which claimed to have exfiltrated hundreds of millions of patient records and demanded a $55 million ransom. - Experts argue that resilience, not prevention alone, now defines healthcare security, with constant low-level disruptions eroding clinical workflows and patient safety.
- Regeneron Pharmaceuticals, co-founded in 1988 by Dr. Leonard S. Schleifer, has grown into a global biopharma leader with a diverse portfolio spanning ophthalmology, immunology, oncology, and rare diseases. - The company's commercial model relies on major pharmaceutical wholesalers—McKesson, AmerisourceBergen, and Cardinal Health—as well as direct government contracts, notably with the U.S. Department of Health and Human Services for REGEN-COV. - Key products include EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for skin cancers, Praluent for cardiovascular conditions, and Kevzara for rheumatoid arthritis. - The executive leadership team, including CSO Dr. George D. Yancopoulos and CFO Christopher Fenimore, combines deep scientific expertise with strategic financial oversight to drive the company's R&D and commercial operations.
- A panel of advanced therapeutics leaders discussed strategic planning, operational readiness, and financial sustainability for cell and gene therapy programs at academic medical centers. - Panelists emphasized that governance success depends on identifying institutional champions across pharmacy, managed care, financial clearance, legal, and clinical teams organized into a centralized steering structure. - Payer variability remains the most persistent challenge a decade into CAR-T therapy, with prior authorization approval not guaranteeing payment and reimbursement models varying dramatically across payers. - The panel expressed optimism about allogeneic and in vivo therapies streamlining delivery and expanding community access, while flagging that volume growth may require rethinking the buy-and-bill paradigm.
- More than half of all cancer patients now receive care in independent community settings, making these practices the frontline of oncology delivery. - The US Oncology Network's 2025 Annual Report highlights AI-powered tools like ambient scribes that reclaim over two hours of clinician time per week. - Partnerships with Sarah Cannon Research Institute and Genospace are expanding clinical trial access and precision medicine capabilities in community settings. - Rising administrative burden, staffing pressures, and financial strain threaten practice sustainability, requiring infrastructure that absorbs complexity before it reaches the clinic.
- Cencora announced a $1.1 billion acquisition of EyeSouth Partners' retina business to strengthen its specialty medical services division. - The deal will integrate EyeSouth's retina-focused physicians into Cencora's existing eye-care arm, Retina Consultants of America. - This marks the third major retina-focused eye-care network acquisition by a distributor, following similar moves by competitors in the consolidating market. - The transaction is expected to be slightly accretive to adjusted earnings per share in the first twelve months after closing.
